ACUTE MYELOID LEUKEMIA (AML)
Clinical trials for ACUTE MYELOID LEUKEMIA (AML) explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA (AML) trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA (AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Lab-Made donor cells aim to beat cancer without the side effects
Disease control OngoingThis study is for children and young adults up to age 21 with high-risk blood cancers like leukemia or lymphoma. It tests a transplant using specially treated donor cells from a family member to reduce the risk of the cancer coming back while lowering the chance of a serious side…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
Personalized immune boost may improve stem cell transplant outcomes
Disease control OngoingThis study tests whether giving a personalized dose of a drug called rabbit ATG (r-ATG) before a stem cell transplant helps the immune system recover more quickly and reduces side effects. It includes children and adults with acute leukemia or myelodysplastic syndrome (MDS) who a…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
Could a targeted drug boost transplant success in tough blood cancers?
Disease control OngoingThis early-phase study tests whether adding the drug venetoclax to standard transplant preparation and post-transplant maintenance can safely help prevent cancer return in people with high-risk acute myeloid leukemia, myelodysplastic syndromes, or related blood cancers. About 102…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: Jacqueline Garcia, MD • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New triple therapy targets tough leukemia in older patients
Disease control OngoingThis study tests a combination of three drugs (gilteritinib, venetoclax, and azacitidine) in people newly diagnosed with a fast-growing form of acute myeloid leukemia (AML) that has a specific gene change (FLT3 mutation). Participants are older or have other health issues that pr…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New pill aims to keep leukemia in check for chinese patients
Disease control OngoingThis study looks at how well and how safely the oral drug ONUREG works in Chinese adults with acute myeloid leukemia (AML) who have already achieved remission after chemotherapy. The goal is to see if taking this pill can help keep the cancer from coming back. The study involves …
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
Shorter treatment for tough leukemia shows promise in pilot study
Disease control OngoingThis study tests a new way of giving two drugs (venetoclax and azacitidine) to adults with acute myeloid leukemia (AML) who are too old or sick for standard chemotherapy. Instead of the usual 7 days of azacitidine, this approach uses only 5 days per cycle to reduce side effects l…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: University of Leipzig • Aim: Disease control
Last updated May 11, 2026 20:48 UTC